Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin)...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology Vol. 14; no. 13; pp. 1278 - 1286
Main Authors: Yamada, Yasuhide, Takahari, Daisuke, Matsumoto, Hiroshi, Baba, Hideo, Nakamura, Masato, Yoshida, Kazuhiro, Yoshida, Motoki, Iwamoto, Shigeyoshi, Shimada, Ken, Komatsu, Yoshito, Sasaki, Yasutsuna, Satoh, Taroh, Takahashi, Keiichi, Mishima, Hideyuki, Muro, Kei, Watanabe, Masahiko, Sakata, Yuh, Morita, Satoshi, Shimada, Yasuhiro, Sugihara, Kenichi
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01.12.2013
Elsevier Limited
Subjects:
ISSN:1470-2045, 1474-5488, 1474-5488
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20–80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2l-leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7–13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7–12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86–1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Taiho.
AbstractList Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20–80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2l-leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7–13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7–12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86–1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Taiho.
Summary Background: Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Methods: We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2l-leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7.5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease ( greater than or equal to 20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Findings: Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11.5 months (95% CI 10.7-13.2) in the group assigned to mFOLFOX6 plus bevacizumab and 11.7 months (10.7-12.9) in the group assigned to SOX plus bevacizumab (HR 1.04, 95% CI 0.86-1.27; less than non-inferiority margin of 1.33, pnon-inferiority=0.014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0.0029) and neutropenia (84 [34%] vs 22 [9%]; p<0.0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0.019) and diarrhoea (23 [9%] vs seven [3%]; p=0.0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). Interpretation: SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Funding Taiho.
Summary Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Methods We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20–80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2 l -leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Findings Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7–13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7–12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86–1·27; less than non-inferiority margin of 1·33, pnon-inferiority =0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). Interpretation SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Funding Taiho.
Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m(2) oxaliplatin, 200 mg/m(2)l-leucovorin, 400 mg/m(2) bolus fluorouracil, and 2400 mg/m(2) infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m(2) intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7-13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7-12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86-1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Taiho.
Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Methods We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2 oxaliplatin, 200 mg/m2 -leucovorin, 400 mg/m2 bolus fluorouracil, and 2400 mg/m2 infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7 times 5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease ( greater than or equal to 20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Findings Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11 times 5 months (95% CI 10 times 7-13 times 2) in the group assigned to mFOLFOX6 plus bevacizumab and 11 times 7 months (10 times 7-12 times 9) in the group assigned to SOX plus bevacizumab (HR 1 times 04, 95% CI 0 times 86-1 times 27; less than non-inferiority margin of 1 times 33, pnon-inferiority=0 times 014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis six [2%] of 250 given SOX plus bevacizumab; p=0 times 0029) and neutropenia (84 [34%] 22 [9%]; p<0 times 0001). Grade 3 or higher anorexia (13 [5%] three [1%]; p=0 times 019) and diarrhoea (23 [9%] seven [3%]; p=0 times 0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). Interpretation SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Funding Taiho.
Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.BACKGROUNDStudies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m(2) oxaliplatin, 200 mg/m(2)l-leucovorin, 400 mg/m(2) bolus fluorouracil, and 2400 mg/m(2) infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m(2) intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699.METHODSWe undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m(2) oxaliplatin, 200 mg/m(2)l-leucovorin, 400 mg/m(2) bolus fluorouracil, and 2400 mg/m(2) infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m(2) intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (≥20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699.Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7-13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7-12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86-1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab).FINDINGSBetween Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7-13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7-12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86-1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysis vs six [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%] vs 22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%] vs three [1%]; p=0·019) and diarrhoea (23 [9%] vs seven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab).SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations.INTERPRETATIONSOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations.Taiho.FUNDINGTaiho.
Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Methods We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We enrolled individuals aged 20-80 years who had metastatic colorectal cancer, had an Eastern Cooperative Oncology Group performance status of 0 or 1, had assessable lesions, had received no previous chemotherapy or radiotherapy, could take drugs orally, and had adequate organ function. Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m2oxaliplatin, 200 mg/m2l-leucovorin, 400 mg/m2bolus fluorouracil, and 2400 mg/m2infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 7·5 mg/kg intravenous infusion of bevacizumab and 130 mg/m2intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break). Randomisation was done centrally with the minimisation method, with stratification by institution and whether postoperative adjuvant chemotherapy had been given. Participants, investigators, and data analysts were not masked to treatment assignment. The primary endpoint was progression-free survival (PFS), which was defined as the interval between enrolment and progressive disease (?20% increase in sum of longest dimensions of target lesions from baseline, or appearance of new lesions) or death, whichever came first. The primary analysis was done by modified intention to treat. This trial is registered with the Japan Pharmaceutical Information Center, number JapicCTI-090699. Findings Between Feb 1, 2009, and March 31, 2011, 512 patients underwent randomisation. 256 patients assigned to receive SOX plus bevacizumab and 255 assigned to receive mFOLFOX6 plus bevacizumab were included in the primary analysis. Median PFS was 11·5 months (95% CI 10·7-13·2) in the group assigned to mFOLFOX6 plus bevacizumab and 11·7 months (10·7-12·9) in the group assigned to SOX plus bevacizumab (HR 1·04, 95% CI 0·86-1·27; less than non-inferiority margin of 1·33, pnon-inferiority=0·014). The most common haematological adverse events of grade 3 or higher were leucopenia (21 [8%] of 249 patients given mFOLFOX6 plus bevacizumab included in safety analysisvssix [2%] of 250 given SOX plus bevacizumab; p=0·0029) and neutropenia (84 [34%]vs22 [9%]; p<0·0001). Grade 3 or higher anorexia (13 [5%]vsthree [1%]; p=0·019) and diarrhoea (23 [9%]vsseven [3%]; p=0·0040) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX6 plus bevacizumab. We recorded seven treatment-related deaths (three in the group given mFOLFOX6 plus bevacizumab; four in that given SOX plus bevacizumab). Interpretation SOX plus bevacizumab is non-inferior to mFOLFOX6 plus bevacizumab with respect to PFS as first-line treatment for metastatic colorectal cancer, and could become standard treatment in Asian populations. Funding Taiho.
Author Mishima, Hideyuki
Satoh, Taroh
Shimada, Yasuhiro
Komatsu, Yoshito
Takahashi, Keiichi
Sugihara, Kenichi
Sasaki, Yasutsuna
Yoshida, Kazuhiro
Watanabe, Masahiko
Morita, Satoshi
Iwamoto, Shigeyoshi
Yamada, Yasuhide
Takahari, Daisuke
Nakamura, Masato
Baba, Hideo
Muro, Kei
Sakata, Yuh
Matsumoto, Hiroshi
Yoshida, Motoki
Shimada, Ken
Author_xml – sequence: 1
  givenname: Yasuhide
  surname: Yamada
  fullname: Yamada, Yasuhide
  email: yayamada@ncc.go.jp
  organization: National Cancer Center Hospital, Tokyo, Japan
– sequence: 2
  givenname: Daisuke
  surname: Takahari
  fullname: Takahari, Daisuke
  organization: Aichi Cancer Center Hospital, Nagoya, Japan
– sequence: 3
  givenname: Hiroshi
  surname: Matsumoto
  fullname: Matsumoto, Hiroshi
  organization: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
– sequence: 4
  givenname: Hideo
  surname: Baba
  fullname: Baba, Hideo
  organization: Kumamoto University, Kumamoto, Japan
– sequence: 5
  givenname: Masato
  surname: Nakamura
  fullname: Nakamura, Masato
  organization: Aizawa Hospital, Matsumoto, Japan
– sequence: 6
  givenname: Kazuhiro
  surname: Yoshida
  fullname: Yoshida, Kazuhiro
  organization: Gifu University School of Medicine, Gifu, Japan
– sequence: 7
  givenname: Motoki
  surname: Yoshida
  fullname: Yoshida, Motoki
  organization: Osaka Medical College Hospital, Takatsuki, Japan
– sequence: 8
  givenname: Shigeyoshi
  surname: Iwamoto
  fullname: Iwamoto, Shigeyoshi
  organization: Kansai Medical University Hirakata Hospital, Hirakata, Japan
– sequence: 9
  givenname: Ken
  surname: Shimada
  fullname: Shimada, Ken
  organization: Showa University Northern Yokohama Hospital, Yokohama, Japan
– sequence: 10
  givenname: Yoshito
  surname: Komatsu
  fullname: Komatsu, Yoshito
  organization: Hokkaido University Hospital, Sapporo, Japan
– sequence: 11
  givenname: Yasutsuna
  surname: Sasaki
  fullname: Sasaki, Yasutsuna
  organization: Showa University, Tokyo, Japan
– sequence: 12
  givenname: Taroh
  surname: Satoh
  fullname: Satoh, Taroh
  organization: Osaka University, Suita, Japan
– sequence: 13
  givenname: Keiichi
  surname: Takahashi
  fullname: Takahashi, Keiichi
  organization: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
– sequence: 14
  givenname: Hideyuki
  surname: Mishima
  fullname: Mishima, Hideyuki
  organization: Aichi Medical University, Nagakute, Japan
– sequence: 15
  givenname: Kei
  surname: Muro
  fullname: Muro, Kei
  organization: Aichi Cancer Center Hospital, Nagoya, Japan
– sequence: 16
  givenname: Masahiko
  surname: Watanabe
  fullname: Watanabe, Masahiko
  organization: Kitasato University School of Medicine, Sagamihara, Japan
– sequence: 17
  givenname: Yuh
  surname: Sakata
  fullname: Sakata, Yuh
  organization: Misawa City Hospital, Misawa, Japan
– sequence: 18
  givenname: Satoshi
  surname: Morita
  fullname: Morita, Satoshi
  organization: Kyoto University, Kyoto, Japan
– sequence: 19
  givenname: Yasuhiro
  surname: Shimada
  fullname: Shimada, Yasuhiro
  organization: National Cancer Center Hospital, Tokyo, Japan
– sequence: 20
  givenname: Kenichi
  surname: Sugihara
  fullname: Sugihara, Kenichi
  organization: Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24225157$$D View this record in MEDLINE/PubMed
BookMark eNqNkt9qFDEUxgep2D_6CErAmy3s1CSTzGQVFSm2Cgu92Aq9C5nMGZqaTcZkZnV9T9_HzG6LsCDbq4Rzfuc7JznfcXbgvIMse0nwGcGkfLMgrMI5xYxPSHFaYTbD-c2T7CiFWc6ZEAeb-xY5zI5jvMOYVATzZ9khZZRywquj7M8cBu1XPhg3Ra0dfPBDUNrYKVKuQf6XsqazqjcOdXaIqIZVyv4elqpGKwgxhRY52c-OsZQB10f00_S3aAm9in0KaaS99QF0ryzSymkIaLK4urg-fZtkke_A5VbVkCZKX5Ab10Iwad5-PUUh9fVLE6FB3a2KgArUB6Ps8-xpq2yEF_fnSfbt4vP1-Zd8fnX59fzTPNe8FH0ueCuYUqIWeKY0Y1zVBDDWvG5KThivWEsLACgrqupZ0xS1qDmpSUlLhSltipNsstXtgv8xQOxlGkaDtcqBH6IkFSeUVqLgj0NJkVa0H2UlJaIsCEno6x30Lu3PpTePFJvxYsZFol7dU0O9hEZ2wSxVWMsHGyTg3RbQwccYoJXajLvxrg_KWEmwHE0nN6aTo6MkKeTGdPImVfOd6ocG--o-busgrWhlIMiok0M0NGa0g2y82avwYUdBW-OMVvY7rCH--wsZqcRbkVGDFBuFUeD9_wUeMcBfaiIZIA
CODEN LANCAO
CitedBy_id crossref_primary_10_1016_j_clcc_2019_01_002
crossref_primary_10_1016_j_ejca_2022_04_009
crossref_primary_10_1016_j_bbapap_2017_01_005
crossref_primary_10_1016_j_heliyon_2024_e36464
crossref_primary_10_1038_s41598_021_84279_6
crossref_primary_10_1007_s00535_021_01798_9
crossref_primary_10_1111_cas_14117
crossref_primary_10_1097_MD_0000000000015999
crossref_primary_10_3892_ol_2018_8628
crossref_primary_10_1007_s13193_016_0543_z
crossref_primary_10_1186_s12876_020_01507_5
crossref_primary_10_1007_s10147_020_01646_5
crossref_primary_10_1111_cas_14758
crossref_primary_10_1186_s12885_019_6200_5
crossref_primary_10_3389_fonc_2021_728854
crossref_primary_10_1517_14740338_2016_1146674
crossref_primary_10_1093_jjco_hyx048
crossref_primary_10_1007_s10147_020_01657_2
crossref_primary_10_1016_j_ejca_2022_02_004
crossref_primary_10_1245_s10434_021_10507_y
crossref_primary_10_1245_s10434_019_07172_7
crossref_primary_10_3390_jcm9061772
crossref_primary_10_1007_s11605_021_05122_x
crossref_primary_10_1038_bjc_2017_128
crossref_primary_10_1016_j_ejca_2018_03_026
crossref_primary_10_1186_s12885_019_5696_z
crossref_primary_10_1093_annonc_mdw206
crossref_primary_10_1371_journal_pone_0133133
crossref_primary_10_1016_j_clinthera_2018_05_011
crossref_primary_10_1186_s40064_016_3529_y
crossref_primary_10_1016_j_critrevonc_2016_05_015
crossref_primary_10_1016_j_esmogo_2023_08_006
crossref_primary_10_1016_j_jsps_2019_09_004
crossref_primary_10_3892_ol_2017_7261
crossref_primary_10_1007_s00384_025_04962_2
crossref_primary_10_1186_s12885_017_3526_8
crossref_primary_10_1016_j_clbc_2021_01_018
crossref_primary_10_1016_j_radonc_2015_08_002
crossref_primary_10_1517_14656566_2014_937706
crossref_primary_10_1007_s00595_019_01872_z
crossref_primary_10_1586_17512433_2016_1133285
crossref_primary_10_1016_S1470_2045_18_30140_2
crossref_primary_10_1007_s00280_015_2825_5
crossref_primary_10_3892_mco_2018_1778
crossref_primary_10_1097_DCR_0000000000001927
crossref_primary_10_2217_fon_2022_1284
crossref_primary_10_1136_bmjopen_2016_011454
crossref_primary_10_1016_j_clcc_2016_09_010
crossref_primary_10_1016_j_critrevonc_2020_102877
crossref_primary_10_1002_ags3_12245
crossref_primary_10_1007_s10147_019_01414_0
crossref_primary_10_9738_INTSURG_D_20_00035_1
crossref_primary_10_3390_ijms18040752
crossref_primary_10_1016_j_lungcan_2015_05_022
crossref_primary_10_1186_s40064_016_3491_8
crossref_primary_10_1016_j_pharmthera_2017_02_028
crossref_primary_10_3389_fphar_2024_1374136
crossref_primary_10_1002_cam4_3095
crossref_primary_10_1007_s10637_018_0697_3
crossref_primary_10_1634_theoncologist_2020_0463
crossref_primary_10_1186_s12885_015_1606_1
crossref_primary_10_1111_cas_14020
crossref_primary_10_1007_s00432_023_04909_6
crossref_primary_10_1007_s10637_021_01162_x
crossref_primary_10_1093_jjco_hyac045
crossref_primary_10_1007_s43441_021_00328_2
crossref_primary_10_1016_S1470_2045_13_70533_3
crossref_primary_10_1186_s12885_019_5468_9
crossref_primary_10_1007_s00280_014_2620_8
crossref_primary_10_1016_j_clcc_2016_07_019
crossref_primary_10_1159_000382119
crossref_primary_10_1093_annonc_mdw162
crossref_primary_10_1002_ijc_30127
crossref_primary_10_1007_s12328_021_01525_0
crossref_primary_10_1016_j_clinthera_2025_01_019
crossref_primary_10_1186_s40780_018_0127_x
crossref_primary_10_1007_s00280_017_3336_3
crossref_primary_10_1158_1078_0432_CCR_15_3117
crossref_primary_10_1111_cas_12465
crossref_primary_10_1093_jjco_hyy069
crossref_primary_10_1093_oncolo_oyae235
crossref_primary_10_1007_s11418_017_1113_6
crossref_primary_10_1080_00498254_2023_2283736
crossref_primary_10_23922_jarc_2024_085
crossref_primary_10_3748_wjg_v20_i41_15110
crossref_primary_10_1186_s12876_024_03549_5
crossref_primary_10_1007_s00280_019_03901_7
crossref_primary_10_1007_s10147_015_0895_3
crossref_primary_10_1002_ags3_12023
crossref_primary_10_1016_j_clinthera_2022_11_009
crossref_primary_10_1093_annonc_mdx122
crossref_primary_10_1007_s11096_017_0536_1
crossref_primary_10_3390_cancers16142597
crossref_primary_10_1186_1471_2407_14_883
crossref_primary_10_1007_s00595_015_1276_2
crossref_primary_10_1007_s00280_015_2834_4
crossref_primary_10_4993_acrt_26_101
crossref_primary_10_1007_s00280_019_03855_w
crossref_primary_10_1093_annonc_mdu232
crossref_primary_10_1007_s10147_018_1308_1
crossref_primary_10_1155_2014_146530
crossref_primary_10_3390_cancers14102470
crossref_primary_10_1007_s40265_014_0302_9
crossref_primary_10_3389_fonc_2019_01367
crossref_primary_10_3892_mco_2016_977
crossref_primary_10_1007_s10120_015_0575_z
crossref_primary_10_1007_s10147_025_02804_3
crossref_primary_10_1007_s00280_016_3212_6
crossref_primary_10_1097_MPA_0000000000001879
crossref_primary_10_3892_mco_2018_1791
crossref_primary_10_3892_or_2014_3299
crossref_primary_10_1002_pst_1875
crossref_primary_10_1007_s10120_022_01291_z
crossref_primary_10_1007_s10147_020_01788_6
crossref_primary_10_1245_s10434_023_13928_z
crossref_primary_10_1002_ags3_12071
crossref_primary_10_1007_s11888_014_0216_7
crossref_primary_10_1038_bjc_2015_10
crossref_primary_10_1016_j_clcc_2017_10_015
crossref_primary_10_3892_ol_2021_12991
crossref_primary_10_1038_srep36944
crossref_primary_10_1177_17588359211009001
crossref_primary_10_1186_s40792_020_01021_6
crossref_primary_10_1016_S1470_2045_15_00411_8
crossref_primary_10_1093_annonc_mdx738
crossref_primary_10_1007_s00280_015_2676_0
crossref_primary_10_1038_nrclinonc_2014_51
crossref_primary_10_1111_jgh_13845
crossref_primary_10_1016_j_clcc_2021_03_001
crossref_primary_10_1007_s00216_014_8350_2
crossref_primary_10_1007_s10120_019_00973_5
crossref_primary_10_1159_000381077
crossref_primary_10_1007_s00280_016_3096_5
crossref_primary_10_1007_s10147_015_0850_3
crossref_primary_10_1016_j_tranon_2019_12_011
crossref_primary_10_1016_j_jgo_2017_08_001
crossref_primary_10_1007_s12029_022_00829_9
crossref_primary_10_1186_s12885_021_08690_y
crossref_primary_10_4251_wjgo_v13_i4_295
crossref_primary_10_1159_000369976
crossref_primary_10_2217_fon_15_59
crossref_primary_10_1007_s00270_019_02284_9
crossref_primary_10_1016_j_ejca_2015_03_007
crossref_primary_10_1245_s10434_015_4771_1
crossref_primary_10_1007_s10147_023_02326_w
crossref_primary_10_1136_bmjopen_2021_048833
crossref_primary_10_5301_tj_5000211
crossref_primary_10_1002_ags3_12687
crossref_primary_10_1002_ags3_12720
crossref_primary_10_1007_s00280_024_04648_6
crossref_primary_10_1159_000446107
crossref_primary_10_1007_s00432_019_03109_5
crossref_primary_10_1016_j_critrevonc_2016_03_015
crossref_primary_10_1016_j_ejca_2017_02_009
crossref_primary_10_1517_14740338_2016_1105959
crossref_primary_10_1007_s00280_017_3255_3
crossref_primary_10_1007_s00280_018_3714_5
crossref_primary_10_1007_s11418_015_0921_9
crossref_primary_10_1007_s11523_023_00996_0
crossref_primary_10_1007_s00280_016_3040_8
crossref_primary_10_1080_0284186X_2016_1278459
crossref_primary_10_4081_oncol_2020_442
crossref_primary_10_1016_j_nut_2021_111362
crossref_primary_10_1186_s12885_020_07766_5
crossref_primary_10_1080_14656566_2016_1186649
crossref_primary_10_1111_ajco_13404
crossref_primary_10_3109_0284186X_2016_1161825
crossref_primary_10_1007_s00280_021_04232_2
crossref_primary_10_1007_s10147_017_1101_6
crossref_primary_10_1016_j_ejca_2017_05_022
crossref_primary_10_1245_s10434_019_07735_8
crossref_primary_10_1111_cas_14841
crossref_primary_10_1007_s00384_020_03606_x
crossref_primary_10_1016_j_esmogo_2024_100090
crossref_primary_10_1093_jjco_hyw086
crossref_primary_10_1186_s12885_021_07823_7
crossref_primary_10_1371_journal_pone_0178221
crossref_primary_10_1136_bcr_2015_213548
crossref_primary_10_1007_s10147_019_01485_z
crossref_primary_10_1002_cam4_70940
crossref_primary_10_1186_s40792_017_0338_7
Cites_doi 10.2307/2529712
10.1158/1078-0432.CCR-07-1225
10.1016/S1470-2045(12)70363-7
10.1200/JCO.2007.14.9898
10.1016/S1470-2045(10)70181-9
10.1093/jnci/92.3.205
10.1200/JCO.2004.05.113
10.1111/j.1349-7006.2010.01793.x
10.1200/JCO.2007.15.2090
10.1200/JCO.1991.9.1.191
10.1200/JCO.2005.03.0106
10.1093/annonc/mdm267
10.1200/JCO.2007.14.9930
10.2307/2983527
10.1093/annonc/mdn721
10.1200/JCO.2007.15.4138
10.1200/JCO.2008.16.7759
10.1200/JCO.2004.09.046
10.1093/annonc/mdl336
10.1038/sj.bjc.6604271
ContentType Journal Article
Copyright 2013 Elsevier Ltd
Elsevier Ltd
Copyright © 2013 Elsevier Ltd. All rights reserved.
Copyright Elsevier Limited Jan 2013
Copyright_xml – notice: 2013 Elsevier Ltd
– notice: Elsevier Ltd
– notice: Copyright © 2013 Elsevier Ltd. All rights reserved.
– notice: Copyright Elsevier Limited Jan 2013
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7TO
7X7
7XB
88E
8AO
8C1
8C2
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1016/S1470-2045(13)70490-X
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (Proquest)
Lancet Titles
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
Lancet Titles
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Oncogenes and Growth Factors Abstracts

MEDLINE
Oncogenes and Growth Factors Abstracts
MEDLINE - Academic

Oncogenes and Growth Factors Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7RV
  name: Nursing & Allied Health Database
  url: https://search.proquest.com/nahs
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1474-5488
EndPage 1286
ExternalDocumentID 3146031261
24225157
10_1016_S1470_2045_13_70490_X
S147020451370490X
1_s2_0_S147020451370490X
Genre Clinical Trial, Phase III
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GrantInformation Taiho.
GroupedDBID ---
--K
--M
-RU
.1-
.55
.FO
0R~
123
1B1
1P~
1~5
29L
4.4
457
4CK
4G.
53G
5VS
6PF
7-5
71M
7RV
7X7
88E
8AO
8C1
8C2
8FI
8FJ
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAMRU
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABMAC
ABMZM
ABUWG
ABWVN
ACGFS
ACIEU
ACLOT
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFKRA
AFPUW
AFRHN
AFTJW
AFXIZ
AGHFR
AGQPQ
AHMBA
AIGII
AIIUN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BENPR
BKEYQ
BKOJK
BNPGV
BPHCQ
BVXVI
CCPQU
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
HMCUK
HVGLF
HZ~
IHE
J1W
KOM
M1P
M41
MO0
N9A
NAPCQ
O-L
O9-
OC~
OO-
OZT
P-8
P-9
P2P
PCD
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
R2-
ROL
RPZ
SDG
SEL
SES
SPCBC
SSH
SSZ
T5K
TLN
UKHRP
UV1
WOW
X7M
XBR
Z5R
~HD
3V.
AACTN
AFCTW
AFKWA
AJOXV
ALIPV
AMFUW
RIG
SDF
ABLVK
ABYKQ
AHPSJ
AJBFU
ZA5
9DU
AAYXX
AFFHD
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c568t-85f84aa8b809ac445ab1e00c5bd6514574f23eee672ab9dd3b8b51b1626a022d3
IEDL.DBID 7RV
ISICitedReferencesCount 221
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000327539600040&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1470-2045
1474-5488
IngestDate Wed Oct 01 14:17:35 EDT 2025
Sun Sep 28 00:28:21 EDT 2025
Thu Oct 02 03:54:22 EDT 2025
Tue Oct 07 06:02:58 EDT 2025
Wed Feb 19 01:54:33 EST 2025
Sat Nov 29 07:03:05 EST 2025
Tue Nov 18 21:29:44 EST 2025
Fri Feb 23 02:29:54 EST 2024
Sun Feb 23 10:18:52 EST 2025
Tue Oct 14 19:38:59 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 13
Language English
License Copyright © 2013 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c568t-85f84aa8b809ac445ab1e00c5bd6514574f23eee672ab9dd3b8b51b1626a022d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
PMID 24225157
PQID 1464953958
PQPubID 23462
PageCount 9
ParticipantIDs proquest_miscellaneous_1751227835
proquest_miscellaneous_1751213017
proquest_miscellaneous_1462186311
proquest_journals_1464953958
pubmed_primary_24225157
crossref_citationtrail_10_1016_S1470_2045_13_70490_X
crossref_primary_10_1016_S1470_2045_13_70490_X
elsevier_sciencedirect_doi_10_1016_S1470_2045_13_70490_X
elsevier_clinicalkeyesjournals_1_s2_0_S147020451370490X
elsevier_clinicalkey_doi_10_1016_S1470_2045_13_70490_X
PublicationCentury 2000
PublicationDate 2013-12-01
PublicationDateYYYYMMDD 2013-12-01
PublicationDate_xml – month: 12
  year: 2013
  text: 2013-12-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle The lancet oncology
PublicationTitleAlternate Lancet Oncol
PublicationYear 2013
Publisher Elsevier Ltd
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Limited
References Cassidy, Clarke, Diaz-Rubio (bib4) 2008; 26
Tournigand, Cervantes, Figer (bib15) 2006; 24
Shuster (bib14) 1991; 9
Andre, Tournigand, Mineur (bib16) 2007; 18
Spiegelhalter, Freedman, Parmar (bib19) 1994; 157
Arkenau, Arnold, Cassidy (bib17) 2008; 26
Therasse, Arbuck, Eisenhauer (bib13) 2000; 92
Tournigand, Andre, Achille (bib2) 2004; 22
Shirasaka (bib5) 2009; 39
Pocock, Simon (bib10) 1975; 31
Yen-Revollo, Goldberg, McLeod (bib18) 2008; 14
Yamada, Tahara, Miya (bib7) 2008; 98
Zang, Lee, Park (bib8) 2009; 20
Muro, Boku, Shimada (bib6) 2010; 11
Saltz, Clarke, Diaz-Rubio (bib3) 2008; 26
Hong, Park, Lim (bib9) 2012; 13
Sorbye, Kohne, Sargent, Glimelius (bib11) 2007; 18
Hochster, Hart, Ramanathan (bib12) 2008; 26
Goldberg, Sargent, Morton (bib1) 2004; 22
Haller, Cassidy, Clarke (bib20) 2008; 26
Chuah, Goh, Lee (bib21) 2011; 102
Spiegelhalter (10.1016/S1470-2045(13)70490-X_bib19) 1994; 157
Shirasaka (10.1016/S1470-2045(13)70490-X_bib5) 2009; 39
Arkenau (10.1016/S1470-2045(13)70490-X_bib17) 2008; 26
Goldberg (10.1016/S1470-2045(13)70490-X_bib1) 2004; 22
Zang (10.1016/S1470-2045(13)70490-X_bib8) 2009; 20
Muro (10.1016/S1470-2045(13)70490-X_bib6) 2010; 11
Tournigand (10.1016/S1470-2045(13)70490-X_bib15) 2006; 24
Hong (10.1016/S1470-2045(13)70490-X_bib9) 2012; 13
Sorbye (10.1016/S1470-2045(13)70490-X_bib11) 2007; 18
Chuah (10.1016/S1470-2045(13)70490-X_bib21) 2011; 102
Shuster (10.1016/S1470-2045(13)70490-X_bib14) 1991; 9
Yamada (10.1016/S1470-2045(13)70490-X_bib7) 2008; 98
Haller (10.1016/S1470-2045(13)70490-X_bib20) 2008; 26
Therasse (10.1016/S1470-2045(13)70490-X_bib13) 2000; 92
Yen-Revollo (10.1016/S1470-2045(13)70490-X_bib18) 2008; 14
Andre (10.1016/S1470-2045(13)70490-X_bib16) 2007; 18
Tournigand (10.1016/S1470-2045(13)70490-X_bib2) 2004; 22
Pocock (10.1016/S1470-2045(13)70490-X_bib10) 1975; 31
Cassidy (10.1016/S1470-2045(13)70490-X_bib4) 2008; 26
Hochster (10.1016/S1470-2045(13)70490-X_bib12) 2008; 26
Saltz (10.1016/S1470-2045(13)70490-X_bib3) 2008; 26
24225156 - Lancet Oncol. 2013 Dec;14(13):1244-5
Lancet Oncol. 2014 Jan;15(1):e4
References_xml – volume: 98
  start-page: 1034
  year: 2008
  end-page: 1038
  ident: bib7
  article-title: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
  publication-title: Br J Cancer
– volume: 157
  start-page: 357
  year: 1994
  end-page: 387
  ident: bib19
  article-title: Bayesian approaches to randomized trials
  publication-title: J R Stat Soc
– volume: 11
  start-page: 853
  year: 2010
  end-page: 860
  ident: bib6
  article-title: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
  publication-title: Lancet Oncol
– volume: 31
  start-page: 103
  year: 1975
  end-page: 115
  ident: bib10
  article-title: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
  publication-title: Biometrics
– volume: 18
  start-page: 77
  year: 2007
  end-page: 81
  ident: bib16
  article-title: Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
  publication-title: Ann Oncol
– volume: 26
  start-page: 2006
  year: 2008
  end-page: 2012
  ident: bib4
  article-title: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
  publication-title: J Clin Oncol
– volume: 26
  start-page: 5910
  year: 2008
  end-page: 5917
  ident: bib17
  article-title: Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials
  publication-title: J Clin Oncol
– volume: 13
  start-page: 1125
  year: 2012
  end-page: 1132
  ident: bib9
  article-title: S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
  publication-title: Lancet Oncol
– volume: 102
  start-page: 478
  year: 2011
  end-page: 483
  ident: bib21
  article-title: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
  publication-title: Cancer Sci
– volume: 39
  start-page: 2
  year: 2009
  end-page: 15
  ident: bib5
  article-title: Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas
  publication-title: J Clin Oncol
– volume: 20
  start-page: 892
  year: 2009
  end-page: 896
  ident: bib8
  article-title: Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer
  publication-title: Ann Oncol
– volume: 26
  start-page: 3523
  year: 2008
  end-page: 3529
  ident: bib12
  article-title: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study
  publication-title: J Clin Oncol
– volume: 24
  start-page: 394
  year: 2006
  end-page: 400
  ident: bib15
  article-title: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study
  publication-title: J Clin Oncol
– volume: 26
  start-page: 2118
  year: 2008
  end-page: 2123
  ident: bib20
  article-title: Potential regional differences for the tolerability profiles of fluoropyrimidines
  publication-title: J Clin Oncol
– volume: 22
  start-page: 23
  year: 2004
  end-page: 30
  ident: bib1
  article-title: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
  publication-title: J Clin Oncol
– volume: 92
  start-page: 205
  year: 2000
  end-page: 216
  ident: bib13
  article-title: New guidelines to evaluate the response to treatment in solid tumors
  publication-title: J Natl Cancer Inst
– volume: 14
  start-page: 8
  year: 2008
  end-page: 13
  ident: bib18
  article-title: Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
  publication-title: Clin Cancer Res
– volume: 26
  start-page: 2013
  year: 2008
  end-page: 2019
  ident: bib3
  article-title: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
  publication-title: J Clin Oncol
– volume: 18
  start-page: 1666
  year: 2007
  end-page: 1672
  ident: bib11
  article-title: Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification
  publication-title: Ann Oncol
– volume: 9
  start-page: 191
  year: 1991
  end-page: 192
  ident: bib14
  article-title: Median follow-up in clinical trials
  publication-title: J Clin Oncol
– volume: 22
  start-page: 229
  year: 2004
  end-page: 237
  ident: bib2
  article-title: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
  publication-title: J Clin Oncol
– volume: 31
  start-page: 103
  year: 1975
  ident: 10.1016/S1470-2045(13)70490-X_bib10
  article-title: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
  publication-title: Biometrics
  doi: 10.2307/2529712
– volume: 14
  start-page: 8
  year: 2008
  ident: 10.1016/S1470-2045(13)70490-X_bib18
  article-title: Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1225
– volume: 13
  start-page: 1125
  year: 2012
  ident: 10.1016/S1470-2045(13)70490-X_bib9
  article-title: S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(12)70363-7
– volume: 26
  start-page: 2006
  year: 2008
  ident: 10.1016/S1470-2045(13)70490-X_bib4
  article-title: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.9898
– volume: 11
  start-page: 853
  year: 2010
  ident: 10.1016/S1470-2045(13)70490-X_bib6
  article-title: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70181-9
– volume: 92
  start-page: 205
  year: 2000
  ident: 10.1016/S1470-2045(13)70490-X_bib13
  article-title: New guidelines to evaluate the response to treatment in solid tumors
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/92.3.205
– volume: 22
  start-page: 229
  year: 2004
  ident: 10.1016/S1470-2045(13)70490-X_bib2
  article-title: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.05.113
– volume: 102
  start-page: 478
  year: 2011
  ident: 10.1016/S1470-2045(13)70490-X_bib21
  article-title: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2010.01793.x
– volume: 39
  start-page: 2
  year: 2009
  ident: 10.1016/S1470-2045(13)70490-X_bib5
  article-title: Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas
  publication-title: J Clin Oncol
– volume: 26
  start-page: 2118
  year: 2008
  ident: 10.1016/S1470-2045(13)70490-X_bib20
  article-title: Potential regional differences for the tolerability profiles of fluoropyrimidines
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.15.2090
– volume: 9
  start-page: 191
  year: 1991
  ident: 10.1016/S1470-2045(13)70490-X_bib14
  article-title: Median follow-up in clinical trials
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1991.9.1.191
– volume: 24
  start-page: 394
  year: 2006
  ident: 10.1016/S1470-2045(13)70490-X_bib15
  article-title: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.03.0106
– volume: 18
  start-page: 1666
  year: 2007
  ident: 10.1016/S1470-2045(13)70490-X_bib11
  article-title: Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdm267
– volume: 26
  start-page: 2013
  year: 2008
  ident: 10.1016/S1470-2045(13)70490-X_bib3
  article-title: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.9930
– volume: 157
  start-page: 357
  year: 1994
  ident: 10.1016/S1470-2045(13)70490-X_bib19
  article-title: Bayesian approaches to randomized trials
  publication-title: J R Stat Soc
  doi: 10.2307/2983527
– volume: 20
  start-page: 892
  year: 2009
  ident: 10.1016/S1470-2045(13)70490-X_bib8
  article-title: Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdn721
– volume: 26
  start-page: 3523
  year: 2008
  ident: 10.1016/S1470-2045(13)70490-X_bib12
  article-title: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.15.4138
– volume: 26
  start-page: 5910
  year: 2008
  ident: 10.1016/S1470-2045(13)70490-X_bib17
  article-title: Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.16.7759
– volume: 22
  start-page: 23
  year: 2004
  ident: 10.1016/S1470-2045(13)70490-X_bib1
  article-title: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.09.046
– volume: 18
  start-page: 77
  year: 2007
  ident: 10.1016/S1470-2045(13)70490-X_bib16
  article-title: Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdl336
– volume: 98
  start-page: 1034
  year: 2008
  ident: 10.1016/S1470-2045(13)70490-X_bib7
  article-title: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604271
– reference: 24225156 - Lancet Oncol. 2013 Dec;14(13):1244-5
– reference: - Lancet Oncol. 2014 Jan;15(1):e4
SSID ssj0017105
Score 2.5511205
Snippet Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer....
Summary Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic...
Summary Background: Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic...
Background Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1278
SubjectTerms Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
Cancer therapies
Chemotherapy
Chemotherapy, Adjuvant
Clinical trials
Colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Creatinine
Diarrhea
Disease-Free Survival
Drug Administration Schedule
Drug Combinations
Drug dosages
Ethics
Female
Fluorouracil - administration & dosage
Hematology, Oncology and Palliative Medicine
Humans
Infusions, Intravenous
Japan
Kaplan-Meier Estimate
Leucovorin - administration & dosage
Male
Metastasis
Middle Aged
Neoplasm Staging
Neutrophils
Organoplatinum Compounds - administration & dosage
Oxonic Acid - administration & dosage
Tegafur - administration & dosage
Toxicity
Treatment Outcome
Title Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
URI https://www.clinicalkey.com/#!/content/1-s2.0-S147020451370490X
https://www.clinicalkey.es/playcontent/1-s2.0-S147020451370490X
https://dx.doi.org/10.1016/S1470-2045(13)70490-X
https://www.ncbi.nlm.nih.gov/pubmed/24225157
https://www.proquest.com/docview/1464953958
https://www.proquest.com/docview/1462186311
https://www.proquest.com/docview/1751213017
https://www.proquest.com/docview/1751227835
Volume 14
WOSCitedRecordID wos000327539600040&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251009
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 7X7
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Nursing & Allied Health Database
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251009
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 7RV
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/nahs
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251009
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: BENPR
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database (Proquest)
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251009
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 8C1
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwELZgQ2gv_IYVxmQkHjapZnFi1w4vCKZVPIwyrWPqm-U4jqjUJaVpKsT_yf_DXZJmL2xF4sUPji85JZ_vvtjnO0LeCqm5A8fDhBCSCe0dS2wWMx8J5b0Hn1lHW1yeqtFITybxWbvgVrZhlWubWBvqtHC4Rn4EMxpDIWOpP8x_MKwahburbQmNu2SbIzcGPKvzy24XQTUhjFyogGHa9esTPEfjrvOAR4cK97_Y5CbfdBP3rH3Q8OH_av-IPGjZJ_3YwOUxuePzJ-T-l3Z__Sn5feorV6wwKK9Ps1lVLEDCuumsT22e0uInsPY5Rs_ldD6rSpr4FVz9VV3ZhGJ8B3SNGd88FvuahK4lxZVgeuWXFs82TR3FNNpohkFPh5Bc0IPx1-HF4Xu4LcViXwyA60GjvMgZxpItpgVW4OtTcLtpAbj1KZ1_B-9MI1oXJXlGvg1PLo4_s7bwA3NyoJdMy0wLa3Wig9g6AJFNuA8CJ5N0AARPKpGFESJJhTaJ0zRKdCJ5wuHnzAInSaPnZAt08LuEZrHQIrF6oL0WkmfW61SFgUszHvpBFPSIWH9y49qs6FicY2a68DdEikGkGB6ZGilm0iPvOrF5kxZkk8BgjSezPvMKVtqA49okqP4m6MvW1pSGmzI0QSONwjyqRUFSd5ItnWpo0r88dG8NY3P9nA7DPfKmuwxfFbeYbO6Lqh6DRc4izm8ZoyTmEYTpuWEMFoGRPfKimXLdewZSCaRcqpe3K_mK7IRYuqQOPdojW8tF5V-Te261nJaL_dpQYDtRdauh1cd8n2x_Ohmdnf8B9axx4w
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQMAL90thgJFA2qSaxYlTO0gIIaDatK4gtUN9M47jiEpdU5q2XH4U_4b_wzm57YWtvOyBV8cnOXLO1f58DiHPRKi4BcfDhBAhE8pZFps0Yi4Q0jkHPrNAW3zqyX5fjUbRxw3yq74Lg7DK2iYWhjrJLO6R74JGIxQyCtXr2VeGXaPwdLVuoVGKxYH78Q1StvzV_jv4v899v_t--HaPVV0FmA07asFUmCphjIqVFxkLHJqYO8-zYZx0IHoIpUj9ANmUvomjJAliFYc85hD5G3B4SQDvvUAugh2XmOzJUZPgcVlCJrmQHsMy7yc3hnYHzeA2D3Yknrex0Wm-8LRYt_B53ev_22rdINeq6Jq-KdXhJtlw01vk8mGFH7hNfvfc0mYrBB22aTpZZnOgMHY8aVMzTWj2HbKSGaIDp3Q2WeY0dit4-nN5bGKK-BUYGjC-fi6OlQVrc4o73fTYLQze3RpbimXC0c0AnxZVbk63Bx-6w52X8FqKzcwYKKYDjqbZlCFWbj7OsMNgm0JYkWSgly6hsy8QfdCAFk1X7pCjc1nUu2QTeHD3CU0joURsVEc5JUKeGqcS6Xs2SbnvOoHXIqIWMW2rqu_YfGSiG3gfSqZGydQ80IVk6lGLvGjIZmXZk3UEnVp-dX2nF7yQBse8jlD-jdDllS3NNde5r72SGol5UJACpWooq3CxDAP_5aNbtdrok-80OtMiT5vH8FfxCM1MXbYs5mATt4DzM-bIEOskgjlYMweb3IQtcq9U8WadIWiGpCOUD85m8gm5sjc87Onefv_gIbnqY5uWAma1RTYX86V7RC7Z1WKczx8XRoqSz-et538AiorKgQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQBMv3C-FAUYCaZNqGidO4yAhhDYqppUyqQP1zTiOIyp1SWmacvlp_A_-D-fkthe28rIHXh2f5Mg5V_vzOYQ8E77kBhwPE0L4TEhrWKSTkFlPBNZa8Jkl2uLTMBiN5GQSHm2QX81dGIRVNjaxNNRxZnCPvAcajVDI0Je9pIZFHO0PXs-_MuwghSetTTuNSkQO7Y9vkL7lrw724V8_d93B2-O9d6zuMMCM35dLJv1ECq1lJJ1QG-BWR9w6jvGjuA-RhB-IxPWQ5cDVURjHXiQjn0ccsgANzi_24L2XyOXA63uY-Mm9Fl7Cgwo-yUXgMCz5fnp7qDduB3e4txvg2RubnOUXz4p7S_83uP4_r9wNcq2OuumbSk1ukg2b3iJb72tcwW3ye2gLk60QjNilyazIFkChzXTWpTqNafYdspU5ogZTOp8VOY3sCp7-LE50RBHXAkNjxtfPxbGqkG1OcQecntilxjtdU0OxfDi6H-DToCou6M74w-B49yW8lmKTMwYKa4GjNEsZYugW0ww7D3YphBtxBvpqYzr_AlEJ9WjZjOUO-Xghi3qXbAIP9j6hSSikiLTsSyuFzxNtZRy4jokT7tq-53SIaMRNmboaPDYlmakW9odSqlBKFfdUKaVq0iEvWrJ5VQ5lHUG_kWXV3PUF76TAYa8jDP5GaPPaxuaKq9xVTkWNxNwrSYFStpR1GFmFh__y0e1GhdTpd1r96ZCn7WP4q3i0plObFeUcbO7mcX7OnMDH-olgGtbMweY3fofcq9S9XWcIpiEZ8YMH5zP5hGyBeqvhwejwIbnqYveWEn21TTaXi8I-IlfMajnNF49Le0XJ54tW8z97HtMI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Leucovorin%2C+fluorouracil%2C+and+oxaliplatin+plus+bevacizumab+versus+S-1+and+oxaliplatin+plus+bevacizumab+in+patients+with+metastatic+colorectal+cancer+%28SOFT%29%3A+an+open-label%2C+non-inferiority%2C+randomised+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Yamada%2C+Yasuhide&rft.au=Takahari%2C+Daisuke&rft.au=Matsumoto%2C+Hiroshi&rft.au=Baba%2C+Hideo&rft.date=2013-12-01&rft.issn=1470-2045&rft.volume=14&rft.issue=13&rft.spage=1278&rft.epage=1286&rft_id=info:doi/10.1016%2FS1470-2045%2813%2970490-X&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204513X7158X%2Fcov150h.gif